Buprenorphine-Naloxone: Complete Drug Monograph

Pharmacokinetic Profile

Half-Life

Buprenorphine 24–42 h (SL/buccal)
Naloxone 2–12 h

Metabolism

CYP3A4 N-dealkylation to norbuprenorphine; UGT-mediated glucuronidation

Protein Binding

Buprenorphine ~96% (α/β globulin); naloxone ~45% (albumin)

Bioavailability (SL)

Buprenorphine variable (commonly cited ~30%); sublingual naloxone exposure low

Volume of Distribution

Large; highly lipophilic (extensive tissue distribution)

Clinical Information

Drug Class

Partial opioid agonist combination (MOUD)

Available Doses

Suboxone film/tablet: 2/0.5, 4/1, 8/2, 12/3 mg
Zubsolv tablet: 0.7/0.18, 1.4/0.36, 2.9/0.71, 5.7/1.4, 8.6/2.1, 11.4/2.9 mg

Route

Sublingual or buccal

Renal Adjustment

No formal adjustment in PI

Hepatic Adjustment

Avoid in severe; not recommended for induction in moderate impairment (use buprenorphine monoproduct)

Pregnancy

Continue MOUD; choice of combination vs monoproduct individualized

Lactation

Compatible; relative infant dose <1% of maternal dose

Schedule / Legal Status

DEA Schedule III; X-waiver eliminated by MAT Act (effective Dec 29, 2022)

Generic Available

Yes (sublingual film and tablet)

Boxed / Class Warnings

Life-threatening respiratory depression; risk amplified by benzodiazepines/CNS depressants

Indications

Indication	Approved Population	Therapy Type	Status
Treatment of opioid dependence (opioid use disorder)	Adults; the original Suboxone sublingual tablet labeling extended to ages ≥16. The current Suboxone sublingual film labeling states safety and effectiveness have not been established in pediatric patients	Maintenance therapy as part of complete treatment plan	FDA Approved

Buprenorphine-naloxone is a cornerstone of medication-assisted treatment (MAT, also called medication for opioid use disorder, MOUD) for moderate-to-severe opioid use disorder. The combination product is generally preferred over buprenorphine alone for outpatient maintenance because the naloxone component is poorly absorbed sublingually but exerts antagonist effects if the tablet or film is crushed and injected — providing an abuse-deterrent design. Treatment should be paired with behavioural therapy, counselling, and recovery support, though pharmacotherapy alone provides substantial benefit and should not be withheld if comprehensive psychosocial care is unavailable.

Off-Label Uses

Chronic pain management — particularly in patients with concurrent OUD or high-risk opioid use. Evidence quality: moderate. Doses for pain are typically lower than for OUD and divided BID–TID. The buprenorphine monoproduct (Belbuca buccal film, Butrans patch, Subutex SL) is more commonly used for pain.

Acute opioid withdrawal management — short-course induction without long-term maintenance, including in emergency department settings. Evidence quality: moderate to high (ED-initiated buprenorphine).

Treatment of adolescents under age 16 — used off-label by addiction specialists, supported by AAP and AACAP statements. Evidence quality: low to moderate.

Dose

Dosing

All doses below refer to the Suboxone-equivalent (4:1 buprenorphine:naloxone) sublingual film or tablet. Zubsolv and Bunavail are not bioequivalent on a milligram-for-milligram basis — refer to manufacturer conversion tables when switching between products. Patients should be in objective opioid withdrawal before the first dose to minimize precipitated withdrawal risk. The FDA prescribing information specifies the first dose should be administered when objective signs of moderate opioid withdrawal appear and not less than six hours after the patient’s last short-acting opioid use; in clinical practice, longer waits (12–24 h for short-acting, 24–72 h for long-acting opioids) are commonly used along with a COWS assessment.

Clinical Scenario	Starting Dose	Maintenance Dose	Maximum Dose	Notes
OUD induction — short-acting opioid (heroin, oxycodone, hydrocodone)	2/0.5–4/1 mg SL when objective withdrawal evident	Day 1: titrate in 2 or 4 mg increments at ~2-hour intervals; Day 1 total up to 8/2 mg Day 2: up to 16/4 mg as a single dose	24/6 mg/day (no added benefit above this per FDA PI)	Wait at least 6 h after last short-acting opioid (FDA PI minimum); 12–24 h commonly used clinically with COWS ≥8–13
OUD induction — methadone or long-acting opioid	FDA PI recommends induction with buprenorphine monoproduct (Subutex SL) on Days 1–2, then transition to combination product	Slow titration over several days to maintenance after transition Higher precipitated withdrawal risk than short-acting	24/6 mg/day after transition	Methadone typically weaned to ≤30 mg/day before induction; allow ≥36–72 h since last methadone dose. Consider micro-dosing (low-dose initiation) protocol if standard induction is not tolerated
OUD induction — patients using illicit fentanyl	Either standard induction (with longer pre-induction abstinence and higher COWS threshold) or low-dose initiation (“micro-dosing”) starting at 0.5 mg buprenorphine, escalating over 5–8 days	Reach 8/2–16/4 mg by Day 5–8 with low-dose protocols; overlap with ongoing opioid use during titration	24/6 mg/day	Fentanyl’s lipophilic depot may prolong withdrawal onset and increase precipitated withdrawal risk; protocols are evolving and not yet standardized in FDA labeling
OUD maintenance — stabilized patient	Continue Day 2 dose	4/1–24/6 mg/day SL once daily (PI target 16/4 mg/day)	24/6 mg/day	Most patients stabilize on 12/3–16/4 mg; doses above 24/6 mg not shown to provide added benefit
OUD maintenance — persistent cravings or breakthrough withdrawal	Increase by 2 or 4 mg buprenorphine increments	16/4–24/6 mg/day	24/6 mg/day per FDA	Consider divided BID–TID dosing for breakthrough cravings or pain; reassess adherence and timing
Taper / discontinuation (when patient and clinician agree)	Reduce gradually from stable maintenance dose	Continue gradual reduction; final taper from 2/0.5 mg before stopping	—	No maximum recommended duration of maintenance per FDA PI; many patients benefit from indefinite maintenance. Most relapses occur after taper
Office-based ED initiation	8/2–16/4 mg SL single dose if COWS ≥8	Bridge prescription until outpatient follow-up	Day 1 ≤8/2 mg, Day 2 ≤16/4 mg per FDA PI	“ED-initiated buprenorphine” model improved 30-day treatment engagement in the D’Onofrio JAMA 2015 trial

Population-specific adjustments

Population	Adjustment	Notes
Adolescents	Suboxone tablet labeling extended approval to ≥16 years; current Suboxone film labeling does not establish safety/effectiveness in pediatrics. Off-label use in adolescents under 16 is supported by professional society guidance	Typical effective doses similar to adults; require parental/guardian consent per local law
Pregnancy	Do not discontinue MOUD; either combination product or buprenorphine monoproduct (Subutex) may be used. Dosage adjustments may be required as pregnancy progresses	Untreated OUD in pregnancy is associated with worse outcomes than continued MOUD; expect neonatal opioid withdrawal syndrome (NOWS), generally less severe than methadone-exposed neonates per the MOTHER trial
Mild hepatic impairment	No clinically significant PK changes; no dose adjustment needed	—
Moderate hepatic impairment (Child-Pugh B)	FDA PI: combination product not recommended for induction; may be used cautiously for maintenance if patient was inducted on buprenorphine monoproduct	Naloxone clearance reduced disproportionately to buprenorphine, raising precipitated withdrawal risk
Severe hepatic impairment (Child-Pugh C)	FDA PI: combination product should be avoided — use buprenorphine monoproduct	Naloxone Cmax/AUC increased ~10-fold and ~13-fold respectively in PI PK study
Renal impairment / dialysis	No specific dose reduction	Buprenorphine PK not significantly different in dialysis patients (small study)
Elderly	Decision to prescribe should be made cautiously; monitor for sedation and respiratory depression	FDA PI notes insufficient numbers of patients ≥65 in clinical studies

Clinical Pearl — Administration Technique

Sublingual films must dissolve completely under the tongue; instruct patients not to chew, swallow, or talk during dissolution because swallowed buprenorphine has poor bioavailability and naloxone absorption may rise. Multiple films can be placed simultaneously under the tongue or against the cheek (buccal), but films should be positioned to minimize overlap. If three films are needed, the third is placed only after the first two have dissolved. Consistent dosing technique should be used between visits to maintain steady bioavailability.

Pharmacology

Mechanism of Action

Buprenorphine is a high-affinity partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Its tight receptor binding and slow dissociation produce long-lasting opioid effects while displacing full agonists like heroin or fentanyl from the receptor — explaining both the precipitated-withdrawal risk during induction and the blockade of subsequent illicit opioid effects. The partial-agonist profile creates a ceiling effect on respiratory depression at typical clinical doses, giving buprenorphine a substantially safer overdose profile than methadone or full opioid agonists in non-tolerant individuals.

Naloxone is a potent mu-opioid antagonist with low sublingual or buccal bioavailability but high parenteral bioavailability. When the combination product is taken as directed, naloxone produces no clinically significant effect; if the film or tablet is crushed and injected, naloxone reaches systemic circulation and precipitates withdrawal in opioid-dependent users — an abuse-deterrent design rather than a therapeutic addition.

ADME Profile

Parameter	Value	Clinical Implication
Absorption	Sublingual Tmax ~40 min–3.5 h; sublingual film and tablet are not bioequivalent across all strengths; buccal exposure to naloxone is somewhat higher than sublingual	Use the sublingual route during induction to minimize naloxone exposure and reduce precipitated withdrawal risk
Distribution	Buprenorphine ~96% protein bound (α/β globulin); naloxone ~45% (albumin); large volume of distribution; crosses placenta and BBB	Protein-binding interactions are uncommon clinically; large Vd contributes to long duration of action
Metabolism	Hepatic CYP3A4 N-dealkylation to norbuprenorphine; further glucuronidation by UGT enzymes; naloxone undergoes glucuronidation, N-dealkylation, and 6-oxo reduction	Strong CYP3A4 inhibitors raise buprenorphine levels; inducers reduce them — both can disrupt stable maintenance
Elimination	Buprenorphine SL/buccal mean t½ 24–42 h; naloxone t½ 2–12 h; mass balance shows ~30% urinary and ~70% biliary/faecal excretion (mostly conjugates)	Once-daily dosing sufficient for most patients; long terminal t½ supports alternate-day dosing in selected stable patients

Side Effects

The incidence figures below are taken from the FDA prescribing information adverse-reactions table for Suboxone sublingual tablets 16/4 mg/day vs placebo over a 4-week study (N=107 vs 107). Some withdrawal-spectrum effects (e.g., rhinitis, diarrhoea, back pain) actually occurred more often in the placebo group because the medication treats opioid withdrawal symptoms — incidence rates therefore reflect the imperfect attribution of effects in opioid-dependent populations. Postmarketing and class effects appear in the second tier and are noted as such.

≥10% Very Common (FDA PI Suboxone 16/4 mg vs placebo)

Adverse Effect	Incidence (placebo)	Clinical Note
Headache	36.4% (22.4%)	Most common reported effect; typically improves over the first weeks
Withdrawal syndrome	25.2% (37.4%)	Notably less than placebo because the drug treats withdrawal; persistent symptoms suggest under-dosing or fentanyl exposure
Pain (any location)	22.4% (18.7%)	Includes back, abdominal, and generalized pain; some overlap with withdrawal
Nausea	15.0% (11.2%)	Often transient; antiemetic if persistent — be aware of QT-prolonging interactions with ondansetron in at-risk patients
Insomnia	14.0% (15.9%)	Avoid concurrent benzodiazepines or Z-drugs as first-line; sleep hygiene counselling
Sweating / hyperhidrosis	14.0% (10.3%)	May persist; usually does not warrant discontinuation
Constipation	12.1% (2.8%)	The clearest opioid-class effect distinguishing drug from placebo; PEG, senna, or stimulant laxative
Pain abdomen	11.2% (6.5%)	Usually mild; rule out other GI pathology if persistent or severe

1–10% Common

Adverse Effect	Incidence (or category)	Clinical Note
Vasodilation (flushing)	9.3%	FDA PI 4-week study Suboxone tablets vs placebo (6.5%)
Vomiting	7.5%	FDA PI; if vomiting occurs immediately after dosing, do not redose — wait until next scheduled dose
Chills	7.5%	FDA PI; placebo 7.5% (no clear separation from placebo)
Asthenia / fatigue	6.5%	FDA PI; similar to placebo (6.5%)
Oral hypoesthesia / glossodynia / oral mucosal erythema	Common (most common SL/buccal AE per FDA PI; precise % not reported)	Usually self-limiting; rotate placement site
Peripheral oedema	Postmarketing	Most frequently reported postmarketing AE not seen in pivotal trials
Androgen deficiency / decreased libido / erectile dysfunction	Class effect	Listed as postmarketing class effect of chronic opioid use; check morning testosterone if symptomatic
Stomatitis, glossitis, blistering/ulceration of mouth	Postmarketing	Reported in FDA postmarketing surveillance
Orthostatic hypotension	Class effect	FDA PI; counsel patients to rise slowly

Serious Serious — regardless of frequency

Adverse Effect	Estimated Frequency	Typical Onset	Required Action
Respiratory depression / death	Rare at therapeutic doses; markedly higher with concomitant benzodiazepines, alcohol, other CNS depressants, or parenteral misuse	Within hours of dose, especially during induction or with co-ingestants	Naloxone reversal — higher and repeated doses than for full agonists may be required due to high mu-receptor affinity; ventilatory support; emergency care
Precipitated opioid withdrawal	Most common in inadequately timed inductions; higher in fentanyl-using patients	Within 1–2 h of first dose	Symptomatic care (clonidine, antiemetics); continue buprenorphine and titrate up rather than stop; consider low-dose initiation protocol on retry
Hepatitis / hepatic events	Rare — spectrum from asymptomatic transaminase elevation to case reports of hepatic failure	Weeks to months	Baseline LFTs and periodic monitoring per FDA PI; evaluate for HBV/HCV, concurrent hepatotoxic drugs, ongoing injection use; carefully discontinue with monitoring if drug-induced
Adrenal insufficiency	Rare — opioid class effect, more often after >1 month of use	After ≥1 month of therapy	Confirm with diagnostic testing; physiologic corticosteroid replacement; wean opioid to allow adrenal recovery
Hypersensitivity / anaphylaxis	Rare (postmarketing reports of bronchospasm, angioneurotic oedema, anaphylactic shock)	Any time	Emergency care; permanent discontinuation; documented contraindication to all buprenorphine and naloxone-containing products
Sleep-related breathing disorders (CSA, sleep-related hypoxaemia)	Dose-related	During chronic therapy	Consider opioid dose decrease per best-practice taper if CSA emerges
Serious dental events (caries, abscess, tooth loss)	Postmarketing — added to labelling per FDA Drug Safety Communication January 12, 2022	As early as 2 weeks; later-onset cases also reported	Establish dental care early in treatment; counsel on post-dose oral hygiene; do not stop MOUD because of dental concerns
Neonatal opioid withdrawal syndrome (NOWS)	Expected with prolonged exposure during pregnancy	Usually first days postpartum	Inpatient observation per local NOWS protocol; non-pharmacologic care first-line; pharmacologic treatment for severe symptoms — typically less severe than methadone-exposed neonates per MOTHER trial
Serotonin syndrome	Rare postmarketing reports with concomitant serotonergic agents	Variable	Discontinue buprenorphine if suspected; supportive care

Discontinuation Treatment Retention & Discontinuation Patterns

Adverse-event-driven discontinuation

Low

Top reasons reported: persistent withdrawal symptoms, nausea/vomiting, headache, hepatic enzyme elevation. The FDA PI does not report a single composite AE-discontinuation rate for the combination product.

Real-world treatment retention

Variable

Top reasons for dropout: ongoing illicit use, social/financial barriers, patient choice to stop MOUD, transition to methadone or naltrexone. Retention varies widely across settings; longer retention consistently associates with better outcomes (Cochrane meta-analysis).

Management Pearl — Precipitated Withdrawal During Induction

If symptoms emerge within 1–2 hours of the first dose, the next step is not to stop buprenorphine. Continue dosing at 4–8 mg every 1–2 hours until symptoms abate (often a higher Day 1 total dose) — full receptor occupancy by buprenorphine resolves the partial-agonist withdrawal state. Adjunctive clonidine, ondansetron, and supportive care help symptomatically. Reassure the patient and document — abandoning treatment after a precipitated episode predicts poor long-term retention.

Int

Drug Interactions

Buprenorphine is metabolized primarily by CYP3A4 to the metabolite norbuprenorphine, with secondary glucuronidation. Most clinically significant interactions involve CYP3A4 modulation or pharmacodynamic CNS-depressant additivity. Sublingual naloxone has minimal interaction potential at clinical doses.

Major Benzodiazepines (alprazolam, clonazepam, diazepam, lorazepam)

MechanismAdditive CNS and respiratory depression

EffectIncreased risk of profound sedation, respiratory depression, coma, and death

ManagementFDA explicitly states MOUD should not be categorically denied in benzodiazepine users — taper benzodiazepine while continuing buprenorphine; counsel on overdose risk; co-prescribe naloxone

FDA PI / FDA DSC 2017

Major Other CNS depressants (alcohol, sedatives, hypnotics, anxiolytics, muscle relaxants, antipsychotics, other opioids)

MechanismAdditive CNS depression and respiratory drive suppression

EffectSedation, respiratory depression, increased overdose risk

ManagementCounsel patients; minimize co-prescription where possible; dispense take-home naloxone

FDA PI

Major Opioid antagonists (naltrexone, nalmefene, samidorphan)

MechanismFull opioid antagonist displaces buprenorphine from mu-receptor

EffectAcute precipitated withdrawal; loss of analgesic and stabilizing effect

ManagementAvoid concurrent use; require ≥7-day buprenorphine washout (often longer) before naltrexone induction; confirm opioid-free state

FDA PI / Vivitrol PI

Major MAO inhibitors (phenelzine, tranylcypromine, linezolid, IV methylene blue)

MechanismMay cause serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma)

EffectSevere additive toxicity reported with opioid–MAOI combinations

ManagementFDA PI: not recommended for patients taking MAOIs or within 14 days of stopping

FDA PI

Moderate Strong CYP3A4 inhibitors (macrolides except azithromycin, azole antifungals, protease inhibitors, cobicistat)

MechanismCYP3A4 inhibition reduces buprenorphine clearance

EffectIncreased plasma concentrations; potential for increased or prolonged opioid effects

ManagementFDA PI: consider buprenorphine dose reduction during co-administration; monitor for sedation and respiratory depression; reassess on inhibitor withdrawal

FDA PI / Lexicomp

Moderate CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital, efavirenz, St. John’s wort)

MechanismCYP3A4 induction accelerates buprenorphine clearance

EffectDecreased plasma concentrations — withdrawal symptoms, cravings, treatment destabilization

ManagementFDA PI: anticipate dose increase; monitor for emerging withdrawal; reassess for over-dosing on inducer withdrawal

FDA PI

Moderate Atazanavir (with or without ritonavir)

MechanismElevated buprenorphine and norbuprenorphine levels per FDA PI

EffectIncreased sedation; postmarketing reports of opioid excess

ManagementFDA PI: monitor and reduce buprenorphine dose if warranted

FDA PI

Moderate Methadone (during transition)

MechanismBuprenorphine displaces methadone from mu-receptor; partial-agonist action precipitates withdrawal

EffectPrecipitated withdrawal during transition (not a chronic concomitant therapy)

ManagementWean methadone to ≤30 mg/day; allow ≥36–72 h since last dose; FDA PI recommends induction with buprenorphine monoproduct first

FDA PI / SAMHSA TIP 63

Moderate Serotonergic agents (SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, tramadol, mirtazapine, trazodone, certain muscle relaxants)

MechanismConcomitant opioid–serotonergic drug exposure has been associated with serotonin syndrome

EffectRare serotonin syndrome reports

ManagementCombination is usually clinically necessary (depression and anxiety are highly comorbid in OUD); observe carefully during initiation and dose changes; discontinue buprenorphine if syndrome suspected

FDA PI

Moderate Full opioid agonists for acute pain (morphine, hydromorphone, fentanyl)

MechanismBuprenorphine’s tight receptor binding partially blocks full agonist action

EffectReduced analgesia from full agonists; higher doses than usual may be needed

ManagementCurrent consensus: continue buprenorphine perioperatively in most cases; multimodal analgesia; high-potency full agonist with monitored care if needed

ASAM 2020 / Anesthesiology consensus

Moderate Skeletal muscle relaxants

MechanismBuprenorphine may enhance neuromuscular blockade and add to respiratory depression

EffectIncreased respiratory depression risk

ManagementMonitor closely; consider dose reduction of either agent; consider naloxone co-prescription

FDA PI

Minor Diuretics

MechanismOpioids can reduce diuretic efficacy by increasing antidiuretic hormone release

EffectReduced diuresis

ManagementMonitor weight, oedema, and blood pressure; usually clinically minor

FDA PI

Minor Anticholinergic agents

MechanismAdditive constipation and urinary retention

EffectSevere constipation, paralytic ileus, urinary retention

ManagementPre-emptive bowel regimen; review medication list for redundant anticholinergics

FDA PI

Mon

Monitoring

Monitoring of buprenorphine-naloxone integrates safety surveillance with engagement-focused care: every visit is an opportunity to reinforce treatment, address barriers, and assess for emerging withdrawal, cravings, or concurrent substance use. The FDA PI recommends weekly visits during the first month, with a transition to less-frequent monthly visits once stable.

Treatment engagement Every visit (weekly during induction; up to monthly when stable per FDA PI)
Routine Cravings, withdrawal symptoms (COWS), psychosocial stressors, recovery goals — the most important “monitoring” parameter
Liver function (ALT, AST, bilirubin) Baseline, then periodically during treatment per FDA PI
Routine Repeat sooner if symptoms or risk factors; evaluate for HBV/HCV, concomitant hepatotoxic drugs, or ongoing injection drug use
Hepatitis and HIV screening Baseline, then per ongoing risk
Routine HBV, HCV, HIV — high baseline prevalence in OUD population; HCV cure available with DAA therapy
Urine drug screen (UDS) Baseline; periodically during treatment, frequency individualized
Routine Confirm buprenorphine presence and screen for ongoing illicit use; positive results inform care, not punishment — should not trigger automatic discharge
Pregnancy testing Baseline in patients of reproductive potential; periodic
Routine Pregnancy is not a reason to stop MOUD; counsel on contraception choices and prenatal care planning
Dental examination Establish dental care early; periodic checkups per FDA DSC 2022
Routine FDA Drug Safety Communication January 12, 2022 — connect patients to dental care; counsel on post-dose oral hygiene and hydration
PDMP review Each prescription per state law
Routine Identify undisclosed opioids, benzodiazepines, or multiple prescribers; integrates with treatment planning
Naloxone access Strongly consider co-prescribing per FDA PI; renew periodically
Routine FDA PI: discuss naloxone with patient and caregiver, particularly when initiating or renewing therapy
Cortisol / adrenal axis If clinical suspicion (fatigue, hypotension, hyponatraemia)
Trigger-based 8 AM cortisol; endocrinology referral if abnormal; do not abruptly stop opioid if confirmed
Testosterone / androgen evaluation If symptoms of androgen deficiency (low libido, ED, fatigue, amenorrhea)
Trigger-based FDA PI lists chronic-opioid androgen deficiency as a postmarketing class effect; laboratory evaluation if symptomatic
Mental health screening (PHQ-9, GAD-7) Baseline; repeat at clinical change
Trigger-based Co-occurring depression and anxiety are common and treatable; integrated mental health care improves OUD outcomes
QTc / ECG If risk factors or addition of QT-prolonging drugs
Trigger-based Risk factors: structural heart disease, electrolyte disturbance, concomitant QT-prolonging drugs, methadone history

Contraindications & Cautions

FDA Warnings & Precautions Risks of life-threatening respiratory and CNS depression — concomitant CNS depressants

Buprenorphine has been associated with life-threatening respiratory depression and death. Many postmarketing reports of coma and death involved misuse by self-injection or were associated with concomitant use of buprenorphine and benzodiazepines, alcohol, or other CNS depressants. Despite these risks, MOUD should not be categorically denied to patients taking these drugs — untreated OUD itself carries substantial mortality risk. The clinical priority is to taper benzodiazepines or other CNS depressants over time while continuing buprenorphine, counsel on overdose risk, and dispense take-home naloxone.

FDA Drug Safety Communication, January 12, 2022: serious dental problems including caries, abscesses, and tooth loss have been reported with sublingual and buccal buprenorphine, including in patients without prior dental issues. The benefits of treatment outweigh this risk; counsel on oral hygiene and connect patients to dental care rather than discontinuing therapy.

Contraindications (FDA PI)

Hypersensitivity to buprenorphine or naloxone — anaphylactic shock and other serious hypersensitivity reactions have been reported

Relative Contraindications (Specialist Input Recommended)

Severe hepatic impairment (Child-Pugh C) — combination product should be avoided per FDA PI; use buprenorphine monoproduct
Moderate hepatic impairment — combination product not recommended for induction; may be used cautiously for maintenance after monoproduct induction
Concurrent benzodiazepine prescription — initiate MOUD with explicit benzodiazepine taper plan and addiction or psychiatry consultation
Use within 14 days of MAOI therapy — FDA PI: not recommended
Pregnancy — continue MOUD, but the choice between combination and monoproduct should be individualized; coordinate with maternal-fetal medicine
Significant QTc prolongation or congenital long QT syndrome — particularly relevant for Zubsolv per its label; ECG and electrolyte optimization before initiation
Recent (<7 days) full opioid agonist for chronic pain — coordinate with pain medicine; consider perioperative protocol

Use with Caution (FDA PI)

Compromised respiratory function — COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, pre-existing respiratory depression
Sleep-related breathing disorders — opioids can cause or worsen central sleep apnoea
Mild–moderate hepatic impairment — start at lower doses; monitor LFTs
Elderly / debilitated patients — increased respiratory depression and fall risk
Head injury, intracranial hypertension, or impaired consciousness — may obscure neurologic assessment; opioids elevate CSF pressure
Adrenal insufficiency or hypothyroidism — may worsen with chronic opioid exposure
Biliary tract disease — opioids increase intracholedochal pressure
Acute abdominal conditions — analgesic effect may obscure diagnosis
Driving and operating machinery — counsel during induction and dose adjustment
Opioid-naïve individuals — buprenorphine-naloxone is not appropriate as an analgesic; deaths have been reported with as little as 2 mg in opioid-naïve individuals

Patient Counselling

Purpose of Therapy

Buprenorphine-naloxone is a medical treatment for opioid use disorder. It works by binding to the same brain receptors as opioids like heroin, fentanyl, and oxycodone — but in a way that controls cravings and withdrawal without producing the same high, and with a much lower risk of fatal overdose. It is not a substitute addiction; it is treatment, in the same way that insulin is treatment for diabetes. Many people stay on this medication for years or indefinitely, and that is a good outcome. Stopping medication too early is the most common cause of relapse.

How to Take It

Place the film or tablet under the tongue (or against the cheek for buccal use) and let it dissolve completely. Do not chew or swallow it because the medication will not be absorbed properly. Do not eat or drink during dissolution. Take the dose once daily, ideally at the same time each day. After dissolution, gently rinse the mouth with water and swallow; wait at least an hour before brushing teeth to avoid eroding temporarily softened enamel. Store the medication safely and out of reach of children — even a small dose can be dangerous to someone who is not opioid-tolerant.

Cravings or withdrawal returning before the next dose

Tell patient Cravings late in the day usually mean the dose is too low or wears off too quickly. We can adjust the dose, split it into morning and evening, or change the timing — this is fine to do and a normal part of finding the right dose.

Call prescriber If cravings or withdrawal are interfering with daily life, work, or sleep, or if you feel close to using illicit opioids — call within 24–48 hours so we can adjust the plan rather than waiting for the next visit.

Overdose risk and naloxone

Tell patient Buprenorphine is much safer than other opioids, but overdose can still happen — especially if combined with alcohol, benzodiazepines, sleeping pills, or if you use illicit opioids. Always have naloxone (Narcan) at home; teach a household member how to use it. After a period off opioids — including jail, detox, or hospitalization — your tolerance is lower and overdose risk is much higher.

Call prescriber If naloxone is used on you for any reason, call right away. If you slip and use illicit opioids, contact us — we will continue treatment, not discharge you.

Dental health

Tell patient Sublingual buprenorphine has been linked to dental problems — cavities, gum disease, infections, and tooth loss — even in people without prior dental issues. After the film dissolves, gently swish water in the mouth and swallow. Wait at least an hour before brushing teeth to avoid eroding temporarily softened enamel. See a dentist within the first months of treatment and at least once a year.

Call prescriber If dental pain, tooth loosening, or new mouth sores develop — let us know so we can connect you to dental care. Do not stop the medication on your own because of dental concerns; we can manage both.

Sedation and driving

Tell patient Until you know how the medication affects you — usually the first 1–2 weeks — avoid driving, operating heavy machinery, and other activities that need full alertness. Most patients return to normal function on a stable dose. Combining with alcohol, sleep medications, or anxiety medications dramatically increases sedation and overdose risk.

Call prescriber If you feel unusually drowsy, confused, or have slowed breathing — especially after starting a new medication — contact us or seek emergency care.

Surgery, dental procedures, and acute pain

Tell patient Tell every doctor and dentist that you take buprenorphine — including emergency room staff. For most surgeries, current guidance is to continue buprenorphine, not stop it. Pain after surgery is treatable, but may require higher doses of pain medication than usual or alternative approaches like nerve blocks.

Call prescriber Before any planned surgery or dental procedure, contact us so we can coordinate with the surgical team.

Pregnancy and breastfeeding

Tell patient If you become pregnant or are planning pregnancy, do not stop buprenorphine on your own — stopping leads to relapse and is more dangerous to you and the baby than continuing. Buprenorphine is well-studied in pregnancy and is a recommended treatment. Babies may have a brief withdrawal syndrome that is treatable. Breastfeeding is generally compatible.

Call prescriber As soon as you know you are pregnant — we will coordinate with obstetric care and may discuss whether to switch from the combination product to buprenorphine alone.

Storage and accidental exposure

Tell patient Keep the medication in a locked place away from children, visitors, and anyone not opioid-tolerant. Even one small dose taken accidentally by a child can be life-threatening. Dispose of unused films via take-back programs or per FDA disposal recommendations.

Call prescriber If anyone takes your medication by mistake — call poison control (1-800-222-1222 in the US) and seek emergency care immediately.

Ref

Sources

Regulatory (PI / FDA Communications)

Suboxone (buprenorphine and naloxone) sublingual film — US Prescribing Information. Indivior Inc. accessdata.fda.gov/drugsatfda_docs/label/2021/022410s042lbl.pdf Primary US regulatory document — source for indications, dosing, contraindications, drug interactions, and adverse-reaction frequencies cited in this monograph.
FDA Drug Safety Communication. Buprenorphine: FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. January 12, 2022. fda.gov/safety/medical-product-safety-information/buprenorphine-drug-safety-communication-fda-warns-about-dental-problems-buprenorphine-medicines Basis for the dental adverse-effect labelling addition and counselling guidance.
Zubsolv (buprenorphine and naloxone) sublingual tablet — US Prescribing Information. Orexo US, Inc. accessdata.fda.gov/drugsatfda_docs/label/2022/204242s016lbl.pdf Reference for QTc data and product-specific dose conversion.

Key Clinical Trials

Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949-958. doi.org/10.1056/NEJMoa022164 Pivotal randomized trial supporting US approval of office-based buprenorphine-naloxone treatment.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. doi.org/10.1002/14651858.CD002207.pub4 Cochrane meta-analysis establishing buprenorphine efficacy versus placebo and head-to-head with methadone.
D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644. doi.org/10.1001/jama.2015.3474 Foundational trial for ED-initiated buprenorphine, supporting the bridging-prescription model.

Guidelines & Regulatory Policy

Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP21-02-01-002. Rockville, MD: SAMHSA; 2021. library.samhsa.gov/product/tip-63-medications-opioid-use-disorder/pep21-02-01-002 Primary US clinical guidance for MOUD induction, maintenance, and special populations.
American Society of Addiction Medicine. National Practice Guideline for the Treatment of Opioid Use Disorder — 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1-91. doi.org/10.1097/ADM.0000000000000633 ASAM consensus on dosing, perioperative management, pregnancy, and integration with psychosocial care.
Substance Abuse and Mental Health Services Administration. Waiver Elimination (MAT Act): Section 1262 of the Consolidated Appropriations Act, 2023 (Mainstreaming Addiction Treatment Act). samhsa.gov/substance-use/treatment/statutes-regulations-guidelines/mat-act Regulatory basis for current prescribing scope — any DEA registrant with Schedule III authority can now prescribe buprenorphine for OUD; effective immediately upon enactment December 29, 2022.
American College of Obstetricians and Gynecologists. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Reaffirmed 2022. acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy Obstetric guidance supporting MOUD continuation in pregnancy and shared decision-making on combination versus monoproduct.

Mechanistic / Basic Science

Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004;2(4):395-402. doi.org/10.2174/1570159043359477 Mechanistic review of partial agonism, kappa antagonism, and slow receptor dissociation underlying clinical features.
Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93-103. doi.org/10.1097/ADM.0000000000000457 Comprehensive review of buprenorphine PK including comparison of sublingual, buccal, and depot products.

Pharmacokinetics / Special Populations

Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661-680. doi.org/10.2165/00003088-200544070-00001 Foundational PK review used for protein binding, distribution, and metabolism statements.
Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331. doi.org/10.1056/NEJMoa1005359 MOTHER trial — buprenorphine-exposed neonates required less morphine and shorter hospital stay than methadone-exposed.
Hämmig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99-105. doi.org/10.2147/SAR.S109919 Original description of micro-dosing (low-dose initiation) buprenorphine without prerequisite withdrawal.
Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict. 2021;30(4):305-315. doi.org/10.1111/ajad.13135 Systematic review supporting low-dose initiation protocols, particularly relevant for fentanyl-using and methadone-transitioning patients.
Antoine D, Huhn AS, Strain EC, et al. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine/naloxone. Am J Addict. 2021;30(1):83-87. doi.org/10.1111/ajad.13069 Case series describing a revised induction strategy with extended pre-dose abstinence in fentanyl-exposed patients.